Interpace Piotroski F Score

IDXG
 Stock
  

USD 1.10  0.04  3.51%   

This module uses fundamental data of Interpace Biosciences to approximate its Piotroski F score. Interpace Biosciences F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Interpace Biosciences. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Interpace Biosciences financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Please see Interpace Biosciences Altman Z Score, Interpace Biosciences Correlation, Interpace Biosciences Valuation, as well as analyze Interpace Biosciences Alpha and Beta and Interpace Biosciences Hype Analysis.
  
Interpace Biosciences Long Term Debt to Equity is projected to slightly decrease based on the last few years of reporting. The past year's Long Term Debt to Equity was at 0.09. The current year Debt to Equity Ratio is expected to grow to 0.09, whereas Debt Current is forecasted to decline to about 1 M. Interpace Biosciences PPandE Turnover is projected to decrease significantly based on the last few years of reporting. The past year's PPandE Turnover was at 7.24. The current year Receivables Turnover is expected to grow to 2.88, whereas Return on Investment is forecasted to decline to (87.27) .
At this time, it appears that Interpace Biosciences' Piotroski F Score is Poor. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
4.0
Piotroski F Score - Poor
1
Current Return On AssetsNegativeFocus
2
Change in Return on AssetsDecreasedFocus
3
Cash Flow Return on AssetsNegativeFocus
4
Current Quality of Earnings (accrual)ImprovingFocus
5
Asset Turnover GrowthIncreaseFocus
6
Current Ratio ChangeIncreaseFocus
7
Long Term Debt Over Assets ChangeLower LeverageFocus
8
Change In Outstending SharesIncreaseFocus
9
Change in Gross MarginNo ChangeFocus

Interpace Biosciences Piotroski F Score Drivers

The critical factor to consider when applying the Piotroski F Score to Interpace Biosciences is to make sure Interpace is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Interpace Biosciences' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Interpace Biosciences' financial numbers are properly reported.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares Diluted3.6 M3.4 M
Significantly Up
Increasing
Slightly volatile
Weighted Average Shares3.6 M3.4 M
Significantly Up
Increasing
Slightly volatile
Net Cash Flow from Operations(22.4 M)(21.8 M)
Fairly Down
Decreasing
Slightly volatile
Current Liabilities25.8 M19.9 M
Significantly Up
Decreasing
Slightly volatile
Total Liabilities43.1 M34.3 M
Significantly Up
Decreasing
Slightly volatile
Gross Margin29.2930.62
Sufficiently Down
Increasing
Slightly volatile
Total Debt11.2 M12.6 M
Fairly Down
Decreasing
Slightly volatile
Asset Turnover0.480.47
Fairly Up
Decreasing
Slightly volatile
Current Assets19.3 M18.8 M
Fairly Up
Decreasing
Slightly volatile
Total Assets87.1 M79.4 M
Significantly Up
Decreasing
Slightly volatile

Interpace Biosciences F Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Interpace Biosciences' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Interpace Biosciences in a much-optimized way.

About Interpace Biosciences Piotroski F Score

F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.

Book Value per Share

(10.53)

Interpace Biosciences Book Value per Share is projected to decrease significantly based on the last few years of reporting. The past year's Book Value per Share was at -10.26

Interpace Biosciences Current Valuation Drivers

We derive many important indicators used in calculating different scores of Interpace Biosciences from analyzing Interpace Biosciences' financial statements. These drivers represent accounts that assess Interpace Biosciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Interpace Biosciences' important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Net Income Per Employee(136.22 K)(162.88 K)(136.96 K)(150.15 K)(172.68 K)(186.31 K)
Revenue Per Employee213.92 K211.96 K246.02 K135.28 K121.75 K132.3 K
Average Assets51.18 M46.35 M57.73 M54.44 M41.44 M51.19 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(5.93 M)(12.3 M)(11.66 M)(26.17 M)(30.09 M)(32.47 M)
Earnings Before Interest Taxes and Depreciation Amortization USD(8.49 M)(8.55 M)(21.8 M)(20.35 M)(9.74 M)(10.51 M)
Earnings before Tax(12.61 M)(12.69 M)(26.77 M)(26.4 M)(15.61 M)(16.84 M)
Average Equity34.29 M32.45 M21.43 M(19.48 M)(37.44 M)(38.42 M)
Enterprise Value15.68 M14.87 M23.28 M4.92 M38.78 M41.84 M
Free Cash Flow(15.29 M)(9.12 M)(19.07 M)(15.55 M)(9.03 M)(9.75 M)
Invested Capital(2.8 M)3.85 M13.24 M7.83 M16.31 M17.59 M
Invested Capital Average(4.2 M)2.51 M12.24 M11.56 M11.06 M11.93 M
Market Capitalization27.39 M22.88 M19.1 M12.69 M31.18 M33.16 M
Tangible Asset Value20.49 M18.59 M27.26 M25.9 M22.71 M28.4 M
Working Capital11.72 M9.05 M(782 K)(4.11 M)(3.52 M)(3.61 M)

About Interpace Biosciences Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Interpace Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Interpace Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Interpace Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey. Interpace Diag operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 147 people.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Interpace Biosciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Interpace Biosciences' short interest history, or implied volatility extrapolated from Interpace Biosciences options trading.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Interpace Biosciences using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Interpace Biosciences Altman Z Score, Interpace Biosciences Correlation, Interpace Biosciences Valuation, as well as analyze Interpace Biosciences Alpha and Beta and Interpace Biosciences Hype Analysis. You can also try Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Complementary Tools for analysis

When running Interpace Biosciences price analysis, check to measure Interpace Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Interpace Biosciences is operating at the current time. Most of Interpace Biosciences' value examination focuses on studying past and present price action to predict the probability of Interpace Biosciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Interpace Biosciences' price. Additionally, you may evaluate how the addition of Interpace Biosciences to your portfolios can decrease your overall portfolio volatility.
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Please note, there is a significant difference between Interpace Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Interpace Biosciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Interpace Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.